ABSTRACT
Schizophrenia is a hetrogeneous condition that includes positive, disorganized, dysphoric and negative symptoms. Evidence linking these symptoms to multiple brain regions is increasing suggesting the underlying disruption of one or more fundamental neural circuits (Andreason,1953) . Furthermore, in contrast to earlier theories (e.g. one transmitter, one locus), broad ranges of neurotransmitters at multiple loci are now implicated (Carlsson,1995) .
Conventional antipsychotic agents do not exert therapeutic effects against all domains of schizophrenic pathology e.g. negative or deficit features (Liberman, 1993) . Furthermore, neuroleptic induced adverse events contribute to rates of noncompliance approaching 50% (Kane,1987) . Alternative approaches, implicating other neurotransmitter system have led to the development of novel antipsychotic drugs such as olanzapine polymorph (Meltzer,1991) .
Olanzapine is an atypical antipsychotic with a broad binding and pharmacological profile (Bymaster et al.,1996) . In vitro receptor binding studies showed a high affinity for dopamine D 2 , D 3 and D 4 receptors; all 5-HT 2 receptor subtypes and the 5-HT 6 receptor; muscarinic receptors, especially the M, subtypes; and a1 -adrenergic receptors. In vivo studies showed that olanzapine had potent activity at D 2 and 5HT 2A receptors, but much less activity at D, and muscarinic receptors, and that it inhibited dopaminergic neurons in the A 10 but not the A 9 tract, suggesting that this agent will not cause extrapyramidal side effects (EPS). Microdialysis studies showed that olanzapine increased the extracellular levels of norepinephrine and dopamine, but not 5-HT, in the prefrontal cortex, and increased extracellular dopamine levels in the neostriatum and neucleus accumbens, areas of the brain associated with scizophrenia. Studies of gene expression showed that olanzapine 10 mg/kg also increased FOS expression in the prefrontal cortex, the dorsolateral striatum, and the nucleus accumbens. These findings are consistent with the effectiveness of olanzapine on both negative and positive symptoms and suggest that, with careful dosing, olanzapine should not cause EPS (Bymaster et al.,1996) .
In a series of double blind controlled trials in patients with schizophrenia and schizoaffective disorder, olanzapine appeared superior to conventional dopamine D, antagonist, haloperidol on measures of overall psychotic symptoms, negative symptoms, comorbid mood symptoms and quality of life (Tollefson etal.,1998; Beasley et al ,1997 , Tollefson et al ,1997 However, there is paucity of studies from India evaluating efficacy and safety of olanzapine. Transcultural including racial variations in psychopharmacological research in a nascent area, necessitating clinical trials of drugs in diverse populations
The present study was part of a multicentered clinical trial carried out at 7 centres to assess the safety and efficacy of olanzapine vs haloperidol in the treatment of schizophrenic patients in India. In this report, data from only one centre is being presented.
MATERIAL AND METHOD
Patients were selected from those who were attending outpatient facility or admitted in the ward of Psychiatry Department of PGIMER, Chandigarh
This was an open-label study of total 30 male/female inpatients and out patients between 18 to 65 years of age who met the DSM-IV criteria for schizophrenia (APA.1994) and had an initial score of atleast 3 on the CGI Severity Scale (Guy, 1976) ) were excluded from, the study Patients who qualified all the inclusion criteria at visit 2 were randomly assigned to the treatment group of either olanzapine or haloperidol. Either drug could be subsequently increased by 10 mg/day to 20 mg/day or decreased to a minimum of 5 mg/day as clinically warranted. Patients were assessed at 1 week interval from visit 2 to visit 6 and then after every 2 weeks from visit 6 to 10.
The primary efficacy measure was the mean change from baseline to end point on Brief Psychiatric Rating Scale's (BPRS) total score derived from Positive And Negative Syndrome Scale (PANSS Kay et al.,1986) , Scale for the Assessment of Negative Symptoms (SANS) (Andreason,1983 ), Montgomery -Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) , Hamilton-Anxiety Scale (HAM-A) (Hamilton, 1959) , Clinical Global Impression Scale (CGI) (Guy, 1976) , and Quality of Life Scale (QOL) (Heinrichetal,1984) .
Treatment emergent adverse events including extrapyramidal symptoms were assessed by UKU Side Effect Rating Scale (Lingjaerde et al.,1987) , Simpson Angus Scale (Simpson and Angus, 1970), Barnes Akathisia Rating Scale (Barnes,1989) , and by changes in vital signs and laboratory tests.
RESULTS
A total of 30 patients were included in the study. Of those 30, 27 patients were randomized to treatment group. Two patients were excluded from the study as one patient was found to be positive for Anti-HBc (IgM) and the other patient was positive on HBs Ag. The third patient was excluded from the study because she had tardive dystonia and she got randomized to haloperidol, so the physician decided against exposing the patient to this study drug.
10 patients were randomized to haloperidol and 17 patients were randomized to olanzapine. In haloperidol group 7 patients completed the protocol, 2 patients were lost to follow up and 1 patient was dropped from the study as he developed severe side effects. In olanzapine group 16 patients completed the trial as per protocol and 1 patient was lost to follow up. Thus, 23 patients completed the protocol, 7 in haloperidol group and 16 in olanzapine group.
Results revealed that improvements in mean scores from baseline to the endpoint of Brief Psychiatric Rating Scale (BPRS) total score extracted from Positive and Negative Syndrome Scale (PANSS) was significant in both the groups: olanzapine group (t-5.87 p<01), as well as haloperidol group (t-2.49 p<05). On BPRS positive score too both the groups have shown significant mean improvement from baseline to the endpoint. However, on BPRS -Negative and BPRS -Anxiety subscales, haloperidol group showed no significant mean improvement whereas olanzapine group had shown significant improvement on BPRS negative and BPRS anxiety subscales (Table 1 and 2) .
On positive symptoms, negative symptoms and general psychopathology subscales of Positive and Negative Syndrome Scale (PANSS) both the groups i.e. olanzapine group and haloperidol group had shown significant mean improvement from baseline to the endpoint (Table  1 and 2). On overall psychopathology, based on the CGI Severity Scale, both the groups have shown significant improvement (OLZt=5.96 p<0.01,HALt=3.87p<0.05).
On Montgomery -Asberg Depression Rating Scale (MADRS) and Hamilton -Anxiety Scales (HAM-A), haloperidol group showed no significant mean improvement from baseline to endpoint, whereas, olanzapine group showed significant improvement on both MADRS and HAM-A.
There was no significant improvement on Global Rating of Affective Flattening or Blunting and Alogia subscales of scale for the Assessment of Negative Symptoms (SANS) in both the groups. On global rating of avolition -apathy, anhedonia and attention subscales of SANS as well as on SANS total score, only olanzapine group had shown significant mean change from baseline to endpoint, as compared to haloperidol group.
On Barnes Akathisia Scale and Simpson Angus Scale both groups showed no significant change from baseline to endpoint. The same was true for Quality of Life. Nearly the same trends are noticed upon comparing the mean change in scores from baseline to endpoint and percentage reduction of scores on various rating scales in the two study groups, but for Alogia subscale of SANS, Barnes Akathisia and QOL (Table 3) . Side effects Patients receiving olanzapine did not report epileptic seizures, EPS or any side effects related to CVS, GIT, dermatology, sexual and reproductive functioning Treatment emergent side effects i.e. possibly drug-related undesirable effects or increase in seventy of baseline experiences unrelated to the diagnosis under study, after the initiation of the study -drug revealed that weight gain was the commonest side effect with olanzapine. Sleepiness, increased duration of sleep and asthenia was observed in more number of patients in olanzapine group than haloperidol group.
Pstients receiving haloperidol also did not report epileptic seizures or any side effects related to CVS, GIR, dermatology and sexual functioning. EPS like rigidity and tremors were reported in more number of patients in haloperidol group than olanzapine group. Tension/inner unrest was also reported more in haloperidol group. Results of the study indicate that when compared to haloperidol, olanzapine had equal effect in improving overall psychology, positive symptoms and severity of schizophrenic illness. In clinical studies conducted in its development, olanzapine has shown therapeutic efficacy that is at least comparable (and in some instances superior) to that of conventional antipsychotic drugs (Beasleyetal, 1996 (Beasleyetal, ,1996a (Beasleyetal, , 1997 Tollefson etal, 1997; Tranetal, 1997) .
On negative symptoms, haloperidol group showed significant mean improvement only on PANSS -negative subscale and there was no significant improvement shown by haloperidol group on BPRS -negative, SANS -total, SANSsubscales. Though there was greater difference in mean change of Alogia subscale of SANS in haloperidol group than olanzapine group, but it did not emerge significant.
Olanzapine group showed significant improvement on BPRS-Negative, PANSSNegative Scale, SANS-total and Avolition-apathy, Anhedonia and Attention subscales of SANS. There was no significant improvement on Affective Flattening and Alogia Sub-scales of SANS. Significant superior treatment benefits of olanzapine relative to haloperidol for negative symptoms among patients with schizophrenia have been previously reported (Beasley et al.,1997; Tollefson etal.,1997; Tollefson and Sanger, 1997) . Tollefson and Sanger (1997) demonstrated that high dose olanzapine had significantly greater direct effect than placebo on all SANS dimension except anhedonia-asociality. Olanzapine also demonstrated a significantly greated direct effect than haloperidol on negative symptoms especially on the dimentions of affective-flattening and avolition-apathy. In our study, olanzapine group showed significant improvement on avolitionapathy but not on dimension of affective flattening.
Conventional neuroleptics reportedly fail to provide a sustained reduction in primary or deficit negative symptoms for the majority of patients (Kane and Mayeroff,1989; Liberman,1993) . Negative symptoms impose great suffering on patients by impending their rehabilitation and psychosocial functioning (Breier et al.,1991) . A superior negative symptom outcome is a principal objective in novel antipsychotic drug development (Kirkpatrick & Carpenter, 1995) . Meltzer (1995) commented that a pleotrophic pharmacology (similar to that of olanzapine) may convey a therapeutic advantage in the treatment of negative symptoms.
Olanzapine group showed significant improvement on MADRS and HAM-A scales whereas haloperidol group did not show any significant mean improvement on both MADRS and HAM-A Scales. Secondary depression, which is common in schizophrenia, is predictive of a poorer prognosis, including greater difficulty reintegrating into society and a higher risk of suicide. It has been suggested in the literature (Harrow et al, 1994 ) that neuroleptic drugs may actually induce dysphoria. Tollefson et al (1998) reported data from a double blind, controlled, multicentre trial of treatment of exacerbations of schizophrenia or schizo-affective disorder with olanzapine versus haloperidol and found significant greater improvement in depressive symptoms with olanzapine.
The broad receptor profile of olanzapine may contribute to this treatment differeence. The density of 5-HT 2A receptors, for example, has been reported to be increased among patients with major depression. Accordingly, olanzapine as a potent 5-HT 2A antagonist, may act at these sites, similar to the action of the recently approved antidepressant nefazodone (Nemrick Luecke et al, 1994) . The importance of these mood related findings is clinically relevant regardless of whether they are primary or secondary therapeutic effects (Tollefson etal, 1997) .
Studies have also reported that patients treated with olanzapine show greater improvement in quality of life as compared to patients treated with haloperidol Tollefson et al, 1997; Tollefson and Sanger, 1997; Beasley et al, 1997) . However, in the present study olanzapine group did not show significant improvement in quality of life.
The most common side effects related to olanzapine was weight gain, sleepiness and increased duration of sleep. Our results reaffirm earlier assertions that compared with traditional antipsychotics, olanzapine has a vastly improved extra-pyramidal side-effect profile (Casey 1996) .
In conclusion, the analysis indicate that olanzapine is effective in the improvement of overall psychopathology including positive symptoms, negative symptoms and secondary depressive features and it is safe and well tolerated at dosage between 5 to 20 mg/day However, small sample size and open-label trial are major limitations for any definitive assertions.
